Caxton Corp Arcellx, Inc. Transaction History

Caxton Corp

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 14, 2023	SELL	$17.18 - $33.0 $685,207 - $1.32 Million	-39,884 Reduced 52.35%	36,302 $1.12 Million
Q3 2022 Nov 14, 2022	SELL	$16.67 - $22.04 $425,635 - $562,747	-25,533 Reduced 25.1%	76,186 $1.43 Million
Q2 2022 Aug 15, 2022	BUY	$7.21 - $24.43 $93,001 - $315,122	12,899 Added 14.52%	101,719 $1.84 Million
Q1 2022 May 16, 2022	BUY	$12.97 - $19.14 $1.15 Million - $1.7 Million	88,820 New	88,820 $1.25 Million

204

44.2M

2.23M

907K

Ticker ACLX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 43,819,200
Market Cap $3.31B
Description
Arcellx, Inc., a clinical-stage biotechnology company, engages in the development of various immunotherapies for patients with cancer and other incurable diseases. The company's lead ddCAR product candidate is CART-ddBCMA, which is in phase 1 clinical trial for the treatment of patients with relapsed or refractory (r/r) multiple myeloma (MM). It...

Get notified when there are updates to the investment portfolio of Caxton Corp, based on Form 13F filings with the SEC.

Stay updated on Caxton Corp with notifications on news.